Evotec Releases Preliminary Financial Results for Q2 and H1 2026 Along with Updated Full-Year Outlook

Evotec's Preliminary Financial Results for Q2 and H1 2026

Evotec SE, a prominent global player in the biopharmaceutical sector, has disclosed its preliminary unaudited financial performance for the second quarter and the first half of 2026. This announcement comes as the company positions itself for continued growth amidst changing market dynamics.

Financial Highlights

Based on the preliminary figures, Evotec estimates total Group revenues for the first half of 2026 to be around €300.1 million. However, challenges remain, with an anticipated adjusted Group EBITDA of approximately -€42.7 million. These numbers highlight the ongoing investments and developmental programs that Evotec is pursuing to strengthen its project pipeline and overall business model.

As of June 30, 2026, the company maintains a robust liquidity position, expected to stand at about €465.6 million, providing Evotec with necessary financial flexibility to navigate upcoming challenges and seize new opportunities in the biopharmaceutical space.

Updated Financial Outlook for 2026

Reflecting these preliminary results, Evotec has revised its full-year financial outlook for 2026. The company now anticipates Group revenues to range between €570 million and €610 million (previously projected at €700 million to €780 million). Alongside this, the adjusted Group EBITDA is expected to be between -€70 million and -€105 million, with former guidance indicating a profit range of €0 million to €40 million.

This updated forecast signals a reevaluation of market conditions and a strategic shift in focus towards more sustainable, long-term growth initiatives, prioritizing investment in critical technology and biopharmaceutical advancements.

Conclusion

The forthcoming detailed financial results for the second quarter and the first half of 2026 are slated for release on August 13, 2026. This comprehensive review will provide deeper insights into Evotec's operational efficiencies and future strategies. Investors remain keenly focused on these updates as they hold significant implications for the company's trajectory in the evolving biopharmaceutical landscape.

Evotec remains committed to its core mission: to develop innovative therapies for patients worldwide. With its updated strategies and commitment to R&D, the company aims to continue making substantial contributions to the healthcare sector despite the challenging circumstances inherited from recent market evolutions.

For further inquiries, the company encourages stakeholders to reach out to Dr. Sarah Fakih, who oversees Global Communications and Investor Relations, for any detailed questions regarding the evolving financial landscape and ongoing initiatives at Evotec SE.